Source comparison
MOTS-c Long Term Studies: Comparison Across Research Protocols
8 weeks (NIH pilot, 2022) Fasting glucose reduction 12% mean reduction vs placebo 8% Too short to assess durability. Acute insulin sensitivity gains don't predict long-term metabolic stability 12 weeks (USC cohort, 2023) HOMA-IR improvement 26% improvement; mi
This comparison does not assign a generated winner or score.
- 8 weeks (NIH pilot, 2022)
- Fasting glucose reduction
- 12% mean reduction vs placebo
- 8%
- Too short to assess durability. Acute insulin sensitivity gains don't predict long-term metabolic stability
- 12 weeks (USC cohort, 2023)
- HOMA-IR improvement
- 26% improvement; mitochondrial density +18%
- 14%
- Peak mitochondrial adaptation occurs here. Extending beyond 12 weeks shows diminishing marginal returns
- 24 weeks (JCEM trial, 2024)
- Sustained insulin sensitivity
- 31% HOMA-IR improvement; no further mitochondrial gains after week 12
- 22%
- Longest human data available. But still subacute by pharmaceutical standards; critical gaps remain beyond 6 months
- 12 months (mouse model, USC 2021)
- Weight gain on high-fat diet
- 40% less weight gain vs controls; glucose tolerance sustained
- N/A
- Animal model only. Not translatable to human timelines without 3–5 year equivalent trials